# AQST catalysts: Aquestive Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/aqst/catalysts

> Aquestive Therapeutics, Inc. (AQST) has 5 upcoming catalysts. The next is the Libervant® (diazepam) NDA/BLA submission, Jan 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Aquestive Therapeutics, Inc. |
| Ticker | AQST (Nasdaq) |
| SEC CIK | 1398733 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/aqst |

## Cash runway

Cash $90.3M as of 2026-09-30; quarterly burn $7.0M; about 38.5 months of runway at that rate (XBRL company facts, accession 0001398733-26-000074).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 22, 2019 | [Exservan (riluzole) FDA approval](https://sec-api.dev/pdufa/riluzole) | AQST |  | completed, approved | "NDA212640 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20191122, review_priority STANDARD; sponsor_name AQUESTIVE; product EXSERVAN (RILUZOLE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212640%22)) |
| Aug 2022 | [Libervant® (diazepam) FDA approval](https://sec-api.dev/pdufa/diazepam) | AQST |  | completed, approved | "The FDA granted tentative approval in August 2022 for Libervant for treatment of ARS patients twelve years of age and older, with U.S. market access for Libervant for this age group of patients subject to the expiration of the existing orphan drug market exclusivity of a previously FDA approved nasal spray drug scheduled to expire in January 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000162828025010422/aqst-q424xex991earningsrel.htm)) |
| April 26, 2024 | [AQST-108 FDA approval](https://sec-api.dev/pdufa/aqst-108) | AQST |  | completed, approved | "Received FDA approval on April 26, 2024*" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000162828025011465/corporatepresentationmar.htm)) |
| April 29, 2024 | [Libervant® (diazepam) FDA approval](https://sec-api.dev/pdufa/diazepam) | AQST |  | completed, approved | "On April 29, 2024, we announced that the FDA approved U.S. market access for Libervant in ARS patients between two to five years of age." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1398733/000162828025010506/aqst-20241231.htm)) |
| Jun 2024 | [Anaphylm™ (dibutepinephrine) topline data readout](https://sec-api.dev/pdufa/dibutepinephrine) | AQST |  | completed, positive | "In June 2024, we reported positive topline PK data from the Company's temperature / pH study of Anaphylm." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000074/aqst-20260930.htm)) |
| Oct 2024 | [Aquestive Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed, met | "In October 2024, we reported positive topline data from an OASIS study, meeting both primary and secondary endpoints." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000074/aqst-20260930.htm)) |
| February 14, 2025 | [Libervant® (diazepam) FDA approval](https://sec-api.dev/pdufa/diazepam) | AQST |  | completed, approved | "On February 14, 2025, in a lawsuit brought by Neurelis, the owner of the FDA approved nasal spray Valtoco, against the FDA (Neurelis, Inc. v. Califf, for which the Company joined as a Defendant Intervenor) challenging the FDA's approval of Libervant for ARS patients aged between two and five years, the U.S. District for the District of Columbia issued a final appealable order entering a judgment in favor of Neurelis's motion for summary judgment and vacating the FDA's approval of Libervant." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000042/aqst-20260630.htm)) |
| Mar 2025 | [Anaphylm™ (dibutepinephrine) NDA/BLA submission](https://sec-api.dev/pdufa/dibutepinephrine) | AQST |  | scheduled | "On track to submit Anaphylm™ (epinephrine) Sublingual Film NDA in Q1 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000162828025001229/aqstbusinessupdate2025-f.htm)) |
| March 5, 2025 | [Aquestive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed | "Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000162828025010422/aqst-q424xex991earningsrel.htm)) |
| Q2 2025 | [Libervant® (diazepam) trial start](https://sec-api.dev/pdufa/diazepam) | AQST |  | scheduled | "Plan to open the IND and initiate a Phase 2a study in Q2 2025 Libervant® (diazepam) Buccal Film for patients ages 2-5 years old (epilepsy)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000162828025010422/q42024supplementalearnin.htm)) |
| Q2 2025 | [AQST-108 trial start](https://sec-api.dev/pdufa/aqst-108) | AQST | alopecia areata | scheduled | "The Company remains on track to begin its Phase 2a clinical trial of AQST-108 in patients with AA in the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000162828025010422/aqst-q424xex991earningsrel.htm)) |
| April 1, 2025 | [Aquestive Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed, positive | "The pediatric study in subjects from the ages of 7 to 17 (weight greater than or equal to 30 kgs) was completed with positive topline data reported on April 1, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000074/aqst-20260930.htm)) |
| May 12, 2025 | [Aquestive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed | "Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000162828025024659/q12025-ex991earningsrelease.htm)) |
| June 16, 2025 | [Anaphylm™ (dibutepinephrine) NDA/BLA acceptance](https://sec-api.dev/pdufa/dibutepinephrine) | AQST | Type 1 allergic reactions | completed | "FDA assigns PDUFA target action date of January 31, 2026 WARREN, N.J., June 16, 2025 - Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for Anaphylm™ in the treatment of Type 1 allergic reactions, including anaphylaxis, and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000162828025031455/prndaacceptancedraft6-13.htm)) |
| August 11, 2025 | [Aquestive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed | "Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873325000012/q22025-ex991earningsrelease.htm)) |
| August 14, 2025 | [Anaphylm™ (dibutepinephrine) FDA approval](https://sec-api.dev/pdufa/dibutepinephrine) | AQST |  | completed, approved | "WARREN, N.J., August 14, 2025 - Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a $75 million strategic funding agreement with funds managed by RTW Investments, LP ("RTW"), subject to United States Food and Drug Administration (FDA) approval of Anaphylm™ (epinephrine) Sublingual Film and other conditions." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000114036125031008/ef20053941_ex99-1.htm)) |
| Q4 2025 | [AQST-108 NDA/BLA submission](https://sec-api.dev/pdufa/aqst-108) | AQST | alopecia areata | scheduled | "Aquestive continues to work toward its anticipated submission of an Investigational New Drug Application for AQST-108 for the treatment of alopecia areata (AA) to the FDA in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873325000012/q22025-ex991earningsrelease.htm)) |
| November 5, 2025 | [Aquestive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed | "Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873325000027/q32025-ex991earningsrelease.htm)) |
| 1H 2026 | [AQST-108 trial start](https://sec-api.dev/pdufa/aqst-108) | AQST | alopecia areata | scheduled | "Aquestive plans to initiate its Phase 2a clinical trial of AQST-108, a topical gel formulation for the treatment of alopecia areata (AA), in the first half of 2026, after the launch of Anaphylm." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000162828025024659/q12025-ex991earningsrelease.htm)) |
| January 30, 2026 | [AQST-108 complete response letter (CRL)](https://sec-api.dev/pdufa/aqst-108) | AQST |  | completed, complete response letter | "Until profitability is achieved, if at all, additional capital and/or other financing or funding will be required, which could be material, to develop and commercialize our product pipeline, including AQST-108, to fund additional development and commercial activities, and that are required by the FDA for Anaphylm under the CRL issued to the Company on January 30, 2026, and to meet our other cash requirements, including debt service." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000074/aqst-20260930.htm)) |
| January 30, 2026 | [Nda219870 complete response letter (CRL)](https://sec-api.dev/pdufa/nda219870) | AQST |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA219870_20260130.pdf%22)) |
| January 31, 2026 | [Aquestive Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | scheduled | "The Company is working to understand and resolve the concerns of the FDA prior to the scheduled PDUFA goal date of January 31, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000003/aqst-20260109.htm)) |
| January 31, 2026 | [AQST-108 FDA advisory committee meeting](https://sec-api.dev/pdufa/aqst-108) | AQST |  | scheduled | "Submission Completed NDA Accepted by the FDA Potential Advisory Committee Meeting Q2 2025 Q3 2025 Q4 2025 Q1 2026 PDUFA action date is scheduled for January 31, 2026 Strictly Confidential." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000114036125031374/ef20053945_ex99-1.htm)) |
| January 31, 2026 | [Anaphylm™ (dibutepinephrine) PDUFA date](https://sec-api.dev/pdufa/dibutepinephrine) | AQST | Type 1 allergic reactions | completed, complete response letter | "Anaphylm™ (dibutepinephrine) Sublingual Film The Company is in contact with the U.S. Food and Drug Administration (FDA) to gather further information about the deficiencies presently identified by the FDA in the New Drug Application (NDA) for Anaphylm, with the goal of addressing those deficiencies prior to the scheduled PDUFA action date of January 31, 2026, once disclosed to the Company." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000003/aquestivepressrelease-fi.htm)) |
| January 31, 2026 | [Anaphylm™ (dibutepinephrine) NDA/BLA acceptance](https://sec-api.dev/pdufa/dibutepinephrine) | AQST |  | scheduled | "•FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873325000012/q22025-ex991earningsrelease.htm)) |
| February 2, 2026 | [Anaphylm™ (dibutepinephrine) complete response letter (CRL)](https://sec-api.dev/pdufa/dibutepinephrine) | AQST | Type I allergic reactions | completed, complete response letter | "On February 2, 2026, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on January 30, 2026, for the New Drug Application (NDA) seeking approval of Anaphylm™ (dibutepinephrine) Sublingual Film for the treatment of Type I allergic reactions, including anaphylaxis, in patients weighing 30kg or more (approximately 66 pounds)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000005/aqst-20260130.htm)) |
| March 3, 2026 | [Aquestive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed | "Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/aqst-q425xex991earningsrel.htm)) |
| Q2 2026 | [AQST-108 topline data readout](https://sec-api.dev/pdufa/aqst-108) | AQST |  | scheduled | "Building on these results, the Company successfully completed dosing in a second Phase 1 clinical trial in the first quarter of 2026 and the data readout from the study is expected in the second quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/aqst-q425xex991earningsrel.htm)) |
| Q2 2026 | [Anaphylm™ (dibutepinephrine) topline data readout](https://sec-api.dev/pdufa/dibutepinephrine) | AQST |  | scheduled | "Completed dosing in Phase 1 study and expect data readout in Q2 2026 Strengthened balance sheet provides needed cash to complete Anaphylm approval and progress Anaphylm ex-US" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/q42025supplementalearnin.htm)) |
| May 12, 2026 | [Aquestive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed | "Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000029/q12026-ex991earningsrelease.htm)) |
| Q3 2026 | [Anaphylm™ (dibutepinephrine) NDA/BLA submission](https://sec-api.dev/pdufa/dibutepinephrine) | AQST |  | scheduled | "•Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000041/q22026-ex991earningsrelease.htm)) |
| Aug 2026 | [Anaphylm™ (dibutepinephrine) topline data readout](https://sec-api.dev/pdufa/dibutepinephrine) | AQST |  | completed, positive | "Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000044/ndapressrelease-9x14x202.htm)) |
| August 11, 2026 | [Aquestive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed | "Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000041/q22026-ex991earningsrelease.htm)) |
| September 17, 2026 | [Anaphylm™ (dibutepinephrine) NDA/BLA submission](https://sec-api.dev/pdufa/dibutepinephrine) | AQST | Type I allergic reactions | completed | "On September 17, 2026, the Company issued a press release announcing it has resubmitted its New Drug Application to the U.S. Food and Drug Administration for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000044/aqst-20260914.htm)) |
| September 30, 2026 | [Anaphylm™ (dibutepinephrine) FDA approval](https://sec-api.dev/pdufa/dibutepinephrine) | AQST |  | completed, approved | "Cash Position Supports Anaphylm Review and Launch Preparation 9 $90.3 million in cash and cash equivalents as of September 30, 2026 Potential access to $75 million under a strategic funding agreement with RTW Investments, subject to applicable conditions including FDA approval of Anaphylm An additional $20 million potentially available under the Oaktree Capital Management debt facility, subject to applicable conditions including FDA approval of Anaphylm; no assurance either facility will become available" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000077/corporatepowerpointprese.htm)) |
| November 3, 2026 | [Aquestive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed | "Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/q32026-ex991earningsrelease.htm)) |
| Jan 2027 | [Libervant® (diazepam) NDA/BLA submission](https://sec-api.dev/pdufa/diazepam) | AQST |  | scheduled | "The Company plans to submit an NDA and launch Libervant for these epilepsy patients between 6 to 11 years of age, if approved by the FDA, upon the expiration of the existing orphan drug market exclusivity scheduled to expire in January 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000162828025001229/aqstbusinessupdate2025-f.htm)) |
| March 16, 2027 | [Anaphylm™ (dibutepinephrine) PDUFA date](https://sec-api.dev/pdufa/dibutepinephrine) | AQST | Type I allergic reactions | scheduled | "Anaphylm Regulatory Milestones 18 Q1 2027Q4 2026Q3 2026Q2 2026Q1 2026 NDA Resubmitted Targeted Ex-U.S. filing in Canada PDUFA Goal Date March 16, 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000077/corporatepowerpointprese.htm)) |
| March 16, 2027 | [Anaphylm™ (dibutepinephrine) NDA/BLA submission](https://sec-api.dev/pdufa/dibutepinephrine) | AQST |  | scheduled | "the FDA's review of the Class 2 resubmission of the Anaphylm NDA and potential approval by the March 16, 2027 PDUFA goal date" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/thirdquarter2026earnings.htm)) |
| March 23, 2027 | [Valtoco (valtoco) PDUFA date](https://sec-api.dev/pdufa/valtoco) | AQST |  | scheduled | "Final FDA approval for patients twelve years of age and older is subject to expiration of the orphan drug exclusivity for Valtoco® on January 10, 2027, and final FDA action, with a PDUFA goal date of March 23, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/q32026-ex991earningsrelease.htm)) |
| March 29, 2027 | [Aquestive Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | scheduled | "The Company has also submitted a Type 9 NDA seeking to add patients six to eleven years of age to the label, with a PDUFA goal date of March 29, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/q32026-ex991earningsrelease.htm)) |

## Drugs

- [AQST-108](https://sec-api.dev/pdufa/aqst-108): alopecia areata
- [Libervant® (diazepam)](https://sec-api.dev/pdufa/diazepam): 
- [Anaphylm™ (dibutepinephrine)](https://sec-api.dev/pdufa/dibutepinephrine): type i allergic reactions, type 1 allergic reactions
- [Nda219870](https://sec-api.dev/pdufa/nda219870): 
- [Exservan (riluzole)](https://sec-api.dev/pdufa/riluzole): 
- [Valtoco (valtoco)](https://sec-api.dev/pdufa/valtoco): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/aqst/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AQST catalysts: Aquestive Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/aqst/catalysts

```bibtex
@misc{secapidev_companies_aqst_catalysts_20261116,
  title        = {AQST catalysts: Aquestive Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/aqst/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_aqst_catalysts_20261116","title":"AQST catalysts: Aquestive Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/aqst/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
